Cutler Group LP Anavex Life Sciences Corp. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$7.65 - $14.43 $77,265 - $145,743	10,100 Added 138.36%	17,400 $9,000
Q3 2022 Oct 25, 2022	SELL	$8.9 - $12.86 $1,780 - $2,572	-200 Reduced 2.67%	7,300 $6,000
Q2 2022 Aug 04, 2022	SELL	$7.31 - $12.84 $191,522 - $336,408	-26,200 Reduced 77.74%	7,500 $5,000
Q1 2022 Apr 14, 2022	BUY	$9.74 - $17.69 $327,264 - $594,384	33,600 Added 33600.0%	33,700 $15,000
Q4 2021 Jan 18, 2022	SELL	$16.88 - $23.31 $109,720 - $151,515	-6,500 Reduced 98.48%	100 $0
Q2 2021 Jul 19, 2021	BUY	$10.16 - $28.86 $43,688 - $124,098	4,300 Added 186.96%	6,600 $2,000
Q1 2021 Apr 26, 2021	SELL	$5.17 - $16.13 $96,679 - $301,631	-18,700 Reduced 89.05%	2,300 $4,000
Q4 2017 Jan 17, 2018	SELL	$3.12 - $4.94 $16,224 - $25,688	-5,200 Reduced 19.85%	21,000 $0
Q3 2017 Oct 17, 2017	BUY	$3.42 - $4.87 $89,604 - $127,594	26,200	26,200 $15,000

152

26.5M

674K

811K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $436M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.